- Price
- $44.81
- Day
- +0.70%
- Mkt Cap
- $7.09B
- 52W Range
- $7.50 – $48.00
- Volume
- 1.28M
- Beta
- -0.08
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”), which together with its subsidiaries is one of the largest post-acute healthcare companies in the United States, announced operating results for the second quarter of 2026. Second Quarter 2026 Financial Highlights Revenue was $1.43 billion, an increase of 9.1% over prior year. Net income was $76.3 million, an increase of $25.4 million, or 49.8% from $51.0 million in the prior-year period. Diluted Earnings.
Read full article
PACS Group, Inc. (PACS) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.31 per share a year ago.
Read full article
Investors interested in Medical Services stocks are likely familiar with PACS Group, Inc. (PACS) and Alignment Healthcare (ALHC). But which of these two companies is the best option for those looking for undervalued stocks?
Read full article
SALT LAKE CITY--(BUSINESS WIRE)--PACS Group, Inc. (NYSE: PACS) (“PACS” or the “Company”) announced today that it intends to report its financial results for the second quarter ended June 30, 2026, on Tuesday, August 4, 2026, after the stock market closes. Management will host a call on Wednesday, August 5, 2026, at 11:30 a.m. ET to discuss the financial results and related information.PACS Group invites current and prospective investors to listen to the call via webcast by going to the Investors.
Read full article
PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating PACS Group, Inc. (NYSE: PACS) (“PACS”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/pacs-group/ Recently a federal securities fraud complaint was filed against PACS on behalf of certain investors who purchased shares of the company's stock between April 11, 2024 and December 16, 2024 (the “Wrongdoing Period”). According to t.
Read full article